![]() |
Correspondence Indian Pediatrics 2007; 44:395-396 |
|||||||||||||||||||||||||||||||||||||||||||
Factors Predictive of Remission in Steroid Resistant Nephrotic Syndrome in Children: A Multivariate Analysis |
|||||||||||||||||||||||||||||||||||||||||||
Children with SRNS were treated with one or more of the following therapeutic protocols as described in our earlier study(2). After a mean follow up of 46 (8-148 months) months. 63/128 (49.3%) children attained a remission (Gp I) while 65 (50.7%) continued to have proteinuria (Gp II). On comparing the patients in the two groups, we observed that the mean age of onset of nephrotic syndrome was significantly higher in Gp II (p = 0.0008). Children who had SNR were more likely to attain remission as compared to children who were INR (p = 0.05). Moreover children who had MCD were significantly more likely to attain remission as compared to non-MCD (p = <0.0000l). Children who had received cyclophosphamide (CP) (intravenous or oral) were significantly more likely to achieve a remission, as compared to those who had not received CP (P <0.00001). Also there was a trend towards higher remission rates in those who had received intravenous CP (46/63) as compared to those who had received oral CP (13/25) (p = 0.07). TABLE I Multivariate Analysis for Factors Predictive of Remission
On multivariate analysis we observed that the only factors that correlated with remission were (1) histopathologic evidence of MCD (p = 0.0005), (2) CP therapy (p = 0.0002) (R2 value for the model 0.640) (Table I). As expected, children in Groupp I on follow-up had a significantly lower total protein (p = 0.05), lower serum albumin (p = 0.002), lower GFR (p <0.00001) and a significantly higher serum creatinine (p = 0.002). Further, we observed that CP increased the number of children with SRNS who achieved complete remission regardless of the underlying renal pathology. In conclusion evidence of MCD on histopathology was perhaps the most important predictive factor. CP therapy appears to be beneficial in inducing a remission in these patients regardless of underlying histopathology. This analysis substantiates the observations in earlier studies(2,5). Well-designed trials are needed to assess the benefits and adverse effects of various therapeutic regimens in treating children with SRNS. Sanjeev Gulati,
|